$PRLD News

Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)

Earnings Beat: Prelude Therapeutics Incorporated (NASDAQ:PRLD) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet

D. Boral Capital Initiates Coverage On Prelude Therapeutics with Buy Rating, Announces Price Target of $9

Prelude Therapeutics (PRLD) Presents Preclinical Data for KAT6A Degarader PRT13722 in Breast Cancer

HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Raises Price Target to $8

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026

Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.

Prelude Therapeutics shares are trading higher after the company announced the presentation of new preclinical data from its lead development candidate, PRT13722. The company price a $90 million offering of 18 million shares at $4.44 per share.

Prelude Therapeutics Prices $90M Offering of 18M Shares At $4.44 Per Share

Prelude Therapeutics Announces Presentation Of New Preclinical Data From PRT13722 For The Treatment Of Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Breast Cancer, And Believes That PRT13722 Is A Highly Differentiated, First-In-Class, Orally Bioavailable, Potent And Highly-selective Kat6A Degrader

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

Prelude Therapeutics Announces Poster With Preclinical Data On Its Oral KAT6A Selective Degrader Accepted For Presentation At American Association For Cancer Research Annual Meeting 2026

Citizens Maintains Market Outperform on Prelude Therapeutics, Raises Price Target to $6

Prelude Therapeutics shares are trading higher. The company reported Q4 financial results.